Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).

Cancer immunology, immunotherapy : CII - 1 Oct 2009

Elkord Eyad, Dangoor Adam, Burt Deborah J, Southgate Thomas D, Daayana Sai, Harrop Richard, Drijfhout Jan W, Sherlock David, Hawkins Robert E, Stern Peter L

Abstract excerpt

We have recently reported the results of a phase II trial in which two TroVax [modified vaccinia ankara (MVA) encoding the tumour antigen 5T4] vaccinations were given to patients both pre- and post-surgical resection of liver metastases secondary to colorectal cancer (CRC). 5T4-specific cellular responses were assessed at the entry and 2 weeks after each vaccination by proliferation of fresh lymphocytes and ELISA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Genes, MHC Class I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Lymphocytes, Tumor-Infiltrating

Share to Survival Rate

Share to T-Lymphocytes, Regulatory

Share to Vaccination

Share to Vaccines, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 19221742
DOI: 10.1007/s00262-009-0674-y
PMCID: PMC11029831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).PMID 19221742Read ↗

Immune Characterization of Metastatic Colorectal Cancer Patients Post Reovirus AdministrationSemantic proximity Read ↗

Immune characterization of metastatic colorectal cancer patients post reovirus administration.Semantic proximity Read ↗

Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases.Semantic proximity Read ↗

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.Semantic proximity Read ↗

p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.Semantic proximity Read ↗

Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.Semantic proximity Read ↗

Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastasesSemantic proximity Read ↗

Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin.Semantic proximity Read ↗

Immunodiagnosis and immunotherapy of isolated tumor cells disseminated to bone marrow of patients with colorectal cancer.Semantic proximity Read ↗

Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.Semantic proximity Read ↗

Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice.Semantic proximity Read ↗

A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.